albuterol / budesonide vs Fluticasone Furoate

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Glucocorticoid receptor · full Asthma pipeline

albuterol / budesonide · Airsupra

Marketed by AstraZeneca

Approved in Asthmacombination (SABA + ICS)
Reliable signal

NCT03769090 · Phase 3 · completed

Participants were randomized and quadruple-blinded across two budesonide/albuterol groups and an active albuterol comparator, with 3,132 randomized participants. The primary clinical endpoint was met for both doses: severe exacerbations occurred in 207/1,013 versus 266/1,014 participants for high-dose treatment (hazard ratio 0.733, p<0.001) and 241/1,054 versus 276/1,056 for low-dose treatment (hazard ratio 0.835, p=0.041).

Next expected readout: February 2027 · NCT06422689 (registry estimate)

Reported efficacy

Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212 (met)

Result source: NCT05505734

Fluticasone Furoate · Arnuity Ellipta

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule (corticosteroid)
Partial signal

NCT00603382 · Phase 2 · completed

This was a randomized, double-blind, placebo-controlled trial with about 95 to 110 people per group. Its primary lung-function comparison (trough FEV1) was significant for the 50, 100 and 200 microgram doses but not for the lowest 25 microgram dose, so the primary result is mixed across the doses tested.

Reported efficacy

Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 100 µg OD 0.142 Liters (Standard Error 0.0403) | GW685698X 200 µg OD 0.173 Liters (Standard Error 0.0404) | GW685698X 300 µg OD 0.228 Liters (Standard Error 0.0402) | GW685698X 400 µg OD 0.215 Liters (Standard Error 0.0414) vs Placebo -0.065 Liters (Standard Error 0.0395) | FP 250 µg BID 0.16 Liters (Standard Error 0.0409) (met)

Result source: NCT00603278

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointalbuterol /​ budesonideFluticasone Furoate
Severe exacerbations, annualised rate0.5 vs 0.6vs AS MDI80/180 μg · n 1054NCT03769090
2 other results
  • 0.1 vs 0.3 160/180 μg · n 1209 · Phase 3 · secondary NCT05505734
  • 0.1 vs 0.3 160/180 μg · n 1180 · Phase 3 · secondary NCT05505734
—Trial running · NCT04651777
Trough FEV1, change0.1 vs 0.0+0.1 vs placebo160/180 μg · wk 12 · n 197NCT03847896
3 other results
  • 0.1 vs 0.0 80/180 μg · wk 12 · n 198 · Phase 3 · primary NCT03847896
  • 0.1 vs 0.0 160/180 μg · wk 1 · n 197 · Phase 3 · secondary NCT03847896
  • 0.1 vs 0.0 80/180 μg · wk 1 · n 198 · Phase 3 · secondary NCT03847896
0.4 vs 0.2+0.2 vs placebo100/25 µg OD · wk 12 · n 200NCT01165138
19 other results
  • 0.2 vs 0.0 100 µg OD · wk 24 · n 111 · Phase 3 · primary NCT01159912
  • 0.2 vs 0.0 50 µg OD · wk 12 · n 108 · Phase 3 · primary NCT01436071
  • 0.4 vs 0.2 200/25 µg OD · wk 24 · n 187 · Phase 3 · primary NCT01134042
  • 0.5 vs 0.4 200/25 µg OD · wk 12 · n 337 · Phase 3 · secondary NCT01686633
  • 0.4 vs 0.4 100/25 µg OD · wk 12 · n 334 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 100/25 µg · wk 36 · n 926 · Phase 3 · secondary NCT01086384
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.2 vs -0.1 200 µg OD · wk 8 · n 101 · Phase 2 · primary NCT00603278
  • 0.2 vs -0.0 200 µg OD · wk 8 · n 99 · Phase 2 · primary NCT00603746
  • 0.1 vs -0.1 100 µg OD · wk 8 · n 102 · Phase 2 · primary NCT00603278
  • 0.2 vs -0.0 800 µg OD · wk 8 · n 102 · Phase 2 · primary NCT00603746
  • 0.2 vs -0.0 600 µg OD · wk 8 · n 107 · Phase 2 · primary NCT00603746
  • 0.2 vs -0.1 400 µg OD · wk 8 · n 97 · Phase 2 · primary NCT00603278
  • 0.2 vs -0.0 400 µg OD · wk 8 · n 101 · Phase 2 · primary NCT00603746
  • 0.2 vs -0.1 300 µg OD · wk 8 · n 102 · Phase 2 · primary NCT00603278
  • 0.2 vs 0.1 100 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
  • -0.5 vs -0.8 100/25 µg OD · wk 4.14 · n 46 · Phase 2 · secondary NCT01128569
  • 0.1 vs 0.1 50 µg OD · wk 12 · n 112 · Phase 2 · secondary NCT01563029
  • 0.3 vs 0.1 25 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
ACQ-5, change—Not posted · NCT06502366—Trial running · NCT04651777
OCS dose reduction—Not posted · NCT06502366—Trial running · NCT04651777

Severe exacerbations, annualised rate

albuterol /​ budesonide
0.5 vs 0.6vs AS MDI80/180 μg · n 1054NCT03769090
2 other results
  • 0.1 vs 0.3 160/180 μg · n 1209 · Phase 3 · secondary NCT05505734
  • 0.1 vs 0.3 160/180 μg · n 1180 · Phase 3 · secondary NCT05505734
Fluticasone Furoate
—Trial running · NCT04651777

Trough FEV1, change

albuterol /​ budesonide
0.1 vs 0.0+0.1 vs placebo160/180 μg · wk 12 · n 197NCT03847896
3 other results
  • 0.1 vs 0.0 80/180 μg · wk 12 · n 198 · Phase 3 · primary NCT03847896
  • 0.1 vs 0.0 160/180 μg · wk 1 · n 197 · Phase 3 · secondary NCT03847896
  • 0.1 vs 0.0 80/180 μg · wk 1 · n 198 · Phase 3 · secondary NCT03847896
Fluticasone Furoate
0.4 vs 0.2+0.2 vs placebo100/25 µg OD · wk 12 · n 200NCT01165138
19 other results
  • 0.2 vs 0.0 100 µg OD · wk 24 · n 111 · Phase 3 · primary NCT01159912
  • 0.2 vs 0.0 50 µg OD · wk 12 · n 108 · Phase 3 · primary NCT01436071
  • 0.4 vs 0.2 200/25 µg OD · wk 24 · n 187 · Phase 3 · primary NCT01134042
  • 0.5 vs 0.4 200/25 µg OD · wk 12 · n 337 · Phase 3 · secondary NCT01686633
  • 0.4 vs 0.4 100/25 µg OD · wk 12 · n 334 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 100/25 µg · wk 36 · n 926 · Phase 3 · secondary NCT01086384
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.2 vs -0.1 200 µg OD · wk 8 · n 101 · Phase 2 · primary NCT00603278
  • 0.2 vs -0.0 200 µg OD · wk 8 · n 99 · Phase 2 · primary NCT00603746
  • 0.1 vs -0.1 100 µg OD · wk 8 · n 102 · Phase 2 · primary NCT00603278
  • 0.2 vs -0.0 800 µg OD · wk 8 · n 102 · Phase 2 · primary NCT00603746
  • 0.2 vs -0.0 600 µg OD · wk 8 · n 107 · Phase 2 · primary NCT00603746
  • 0.2 vs -0.1 400 µg OD · wk 8 · n 97 · Phase 2 · primary NCT00603278
  • 0.2 vs -0.0 400 µg OD · wk 8 · n 101 · Phase 2 · primary NCT00603746
  • 0.2 vs -0.1 300 µg OD · wk 8 · n 102 · Phase 2 · primary NCT00603278
  • 0.2 vs 0.1 100 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
  • -0.5 vs -0.8 100/25 µg OD · wk 4.14 · n 46 · Phase 2 · secondary NCT01128569
  • 0.1 vs 0.1 50 µg OD · wk 12 · n 112 · Phase 2 · secondary NCT01563029
  • 0.3 vs 0.1 25 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029

ACQ-5, change

albuterol /​ budesonide
—Not posted · NCT06502366
Fluticasone Furoate
—Trial running · NCT04651777

OCS dose reduction

albuterol /​ budesonide
—Not posted · NCT06502366
Fluticasone Furoate
—Trial running · NCT04651777
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. albuterol / budesonide: 4 of 4 rows · Fluticasone Furoate: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricalbuterol /​ budesonideFluticasone Furoate
Dropout rate
9.9%160/180 μga
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
11.7%80/180 μg
NCT03769090 · Phase 3 · Asthma · phase 3
28.2%160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
3.6%160/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
7.8%80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
—160/180
NCT06245551 · Phase 3
—
NCT05555290 · Phase 3 · registry result, not featured evidence
—
NCT04234464 · Phase 3 · registry result, not featured evidence
—160/180 μg
NCT04848662 · Phase 1 · registry result, not featured evidence
9.5%200 µg ODb
NCT00603382 · Phase 2
show 41 more results
10.9%100 µg OD
NCT00603382 · Phase 2
9%50 µg OD
NCT00603382 · Phase 2
14.4%25 µg OD
NCT00603382 · Phase 2
13.9%200 µg OD
NCT00603278 · Phase 2
16.2%100 µg OD
NCT00603278 · Phase 2
13.1%400 µg OD
NCT00603278 · Phase 2
10.7%300 µg OD
NCT00603278 · Phase 2
18.2%200 µg OD
NCT00603746 · Phase 2
16.7%800 µg OD
NCT00603746 · Phase 2
12.1%600 µg OD
NCT00603746 · Phase 2
7.9%400 µg OD
NCT00603746 · Phase 2
19.3%100 µg OD
NCT01159912 · Phase 3
10.9%100/25 µg OD
NCT01165138 · Phase 3
12.6%200 µg OD
NCT01431950 · Phase 3
16%100 µg OD
NCT01431950 · Phase 3
14.2%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
28%100 µg OD
NCT01563029 · Phase 2
27.5%50 µg OD
NCT01563029 · Phase 2
20.3%25 µg OD
NCT01563029 · Phase 2
13.9%50 mcg
NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy
—
NCT02502734 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
7.2%200/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
9.2%100/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
22.2%50 µg OD
NCT01436110 · Phase 3 · registry result, not featured evidence
11.3%50 µg OD
NCT01436071 · Phase 3 · registry result, not featured evidence
—100/25 µg
NCT01086384 · Phase 3 · registry result, not featured evidence
—200/25 µg OD
NCT01018186 · Phase 3 · registry result, not featured evidence
—100/25 µg OD
NCT01018186 · Phase 3 · registry result, not featured evidence
1.8%200/25 µg PM
NCT01086410 · Phase 3 · registry result, not featured evidence
3.6%100/25 µg PM
NCT01086410 · Phase 3 · registry result, not featured evidence
—100 µg AM
NCT01808339 · Phase 2 · registry result, not featured evidence
—100 µg PM
NCT01808339 · Phase 2 · registry result, not featured evidence
—100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
—100 µg
NCT01332292 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
—200 µg OD
NCT00766090 · Phase 2 · registry result, not featured evidence
—100 µg BID
NCT00766090 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0.7%160/180 μga
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
0.7%80/180 μg
NCT03769090 · Phase 3 · Asthma · phase 3
0.5%160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
1%160/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
0.5%80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
—160/180
NCT06245551 · Phase 3
—
NCT05555290 · Phase 3 · registry result, not featured evidence
—
NCT04234464 · Phase 3 · registry result, not featured evidence
—160/180 μg
NCT04848662 · Phase 1 · registry result, not featured evidence
1.1%200 µg ODb
NCT00603382 · Phase 2
show 41 more results
1.8%100 µg OD
NCT00603382 · Phase 2
1%50 µg OD
NCT00603382 · Phase 2
1%25 µg OD
NCT00603382 · Phase 2
1%200 µg OD
NCT00603278 · Phase 2
2.9%100 µg OD
NCT00603278 · Phase 2
2%400 µg OD
NCT00603278 · Phase 2
0%300 µg OD
NCT00603278 · Phase 2
3%200 µg OD
NCT00603746 · Phase 2
0%800 µg OD
NCT00603746 · Phase 2
0.9%600 µg OD
NCT00603746 · Phase 2
0%400 µg OD
NCT00603746 · Phase 2
1.8%100 µg OD
NCT01159912 · Phase 3
1%100/25 µg OD
NCT01165138 · Phase 3
1.7%200 µg OD
NCT01431950 · Phase 3
1.7%100 µg OD
NCT01431950 · Phase 3
3.6%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
1.7%100 µg OD
NCT01563029 · Phase 2
0.8%50 µg OD
NCT01563029 · Phase 2
0%25 µg OD
NCT01563029 · Phase 2
—50 mcg
NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy
—
NCT02502734 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
0.9%200/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
0.9%100/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
0.9%50 µg OD
NCT01436110 · Phase 3 · registry result, not featured evidence
0%50 µg OD
NCT01436071 · Phase 3 · registry result, not featured evidence
—100/25 µg
NCT01086384 · Phase 3 · registry result, not featured evidence
—200/25 µg OD
NCT01018186 · Phase 3 · registry result, not featured evidence
—100/25 µg OD
NCT01018186 · Phase 3 · registry result, not featured evidence
0%200/25 µg PM
NCT01086410 · Phase 3 · registry result, not featured evidence
0%100/25 µg PM
NCT01086410 · Phase 3 · registry result, not featured evidence
—100 µg AM
NCT01808339 · Phase 2 · registry result, not featured evidence
—100 µg PM
NCT01808339 · Phase 2 · registry result, not featured evidence
—100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
—100 µg
NCT01332292 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
—200 µg OD
NCT00766090 · Phase 2 · registry result, not featured evidence
—100 µg BID
NCT00766090 · Phase 2 · registry result, not featured evidence
Serious AEs
5.2%160/180 μga
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
3.8%80/180 μg
NCT03769090 · Phase 3 · Asthma · phase 3
3.1%160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
1%160/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
2%80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
0%160/180
NCT06245551 · Phase 3
0%
NCT05555290 · Phase 3 · registry result, not featured evidence
0%
NCT04234464 · Phase 3 · registry result, not featured evidence
0%160/180 μg
NCT04848662 · Phase 1 · registry result, not featured evidence
0%200 µg ODb
NCT00603382 · Phase 2
show 41 more results
0.9%100 µg OD
NCT00603382 · Phase 2
0%50 µg OD
NCT00603382 · Phase 2
1%25 µg OD
NCT00603382 · Phase 2
0%200 µg OD
NCT00603278 · Phase 2
0%100 µg OD
NCT00603278 · Phase 2
1%400 µg OD
NCT00603278 · Phase 2
1%300 µg OD
NCT00603278 · Phase 2
2%200 µg OD
NCT00603746 · Phase 2
0%800 µg OD
NCT00603746 · Phase 2
0.9%600 µg OD
NCT00603746 · Phase 2
0%400 µg OD
NCT00603746 · Phase 2
3.5%100 µg OD
NCT01159912 · Phase 3
0%100/25 µg OD
NCT01165138 · Phase 3
3.4%200 µg OD
NCT01431950 · Phase 3
2.5%100 µg OD
NCT01431950 · Phase 3
3%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
0.8%100 µg OD
NCT01563029 · Phase 2
0.8%50 µg OD
NCT01563029 · Phase 2
0%25 µg OD
NCT01563029 · Phase 2
2.5%50 mcg
NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy
0%
NCT02502734 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0.8%100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0%100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
0.3%200/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
1.2%100/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
0%50 µg OD
NCT01436110 · Phase 3 · registry result, not featured evidence
0.8%50 µg OD
NCT01436071 · Phase 3 · registry result, not featured evidence
4.1%100/25 µg
NCT01086384 · Phase 3 · registry result, not featured evidence
0.5%200/25 µg OD
NCT01018186 · Phase 3 · registry result, not featured evidence
1.5%100/25 µg OD
NCT01018186 · Phase 3 · registry result, not featured evidence
0%200/25 µg PM
NCT01086410 · Phase 3 · registry result, not featured evidence
0%100/25 µg PM
NCT01086410 · Phase 3 · registry result, not featured evidence
0%100 µg AM
NCT01808339 · Phase 2 · registry result, not featured evidence
0%100 µg PM
NCT01808339 · Phase 2 · registry result, not featured evidence
0%100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
0%100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
0%100 µg
NCT01332292 · Phase 2 · registry result, not featured evidence
0%100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
0%200 µg OD
NCT00766090 · Phase 2 · registry result, not featured evidence
0%100 µg BID
NCT00766090 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
160/180 μga
nasopharyngitis 7.5%
headache 4.3%
covid-19 3.3%
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
80/180 μg
nasopharyngitis 5.8%
headache 4.7%
covid-19 4.5%
NCT03769090 · Phase 3 · Asthma · phase 3
160/180 μg
upper respiratory tract infection 5.4%
covid-19 5.1%
nasopharyngitis 3.7%
NCT05505734 · Phase 3 · Asthma · phase 3
160/180 μg
nasopharyngitis 7.6% (placebo 5.5%)
headache 5.1% (placebo 7%)
dysphonia 2% (placebo 0%)
NCT03847896 · Phase 3 · Asthma · phase 3
80/180 μg
nasopharyngitis 6.4% (placebo 5.5%)
headache 4.9% (placebo 7%)
upper respiratory tract infection 1.5% (placebo 1%)
NCT03847896 · Phase 3 · Asthma · phase 3
160/180
bronchial irritation 1.6% (placebo 0%)
diarrhoea 0% (placebo 1.6%)
headache 0% (placebo 1.6%)
NCT06245551 · Phase 3
anxiety 1%
cough 1%
covid-19 1%
NCT05555290 · Phase 3 · registry result, not featured evidence
anxiety 0% (placebo 1.7%)
dyspnoea 0% (placebo 1.7%)
NCT04234464 · Phase 3 · registry result, not featured evidence
160/180 μg
miliaria 0%
NCT04848662 · Phase 1 · registry result, not featured evidence
200 µg ODb
headache 5.3% (placebo 10.6%)
nasopharyngitis 3.2% (placebo 1.1%)
oropharyngitis 3.2% (placebo 1.1%)
NCT00603382 · Phase 2
show 40 more results
100 µg OD
headache 10.9% (placebo 10.6%)
nasopharyngitis 3.6% (placebo 1.1%)
oropharyngitis 3.6% (placebo 1.1%)
NCT00603382 · Phase 2
50 µg OD
headache 6% (placebo 10.6%)
back pain 3% (placebo 0%)
oropharyngitis 1% (placebo 1.1%)
NCT00603382 · Phase 2
25 µg OD
headache 6.2% (placebo 10.6%)
back pain 0% (placebo 0%)
nasopharyngitis 0% (placebo 1.1%)
NCT00603382 · Phase 2
200 µg OD
headache 7.9% (placebo 5.6%)
nasopharyngitis 5% (placebo 7.5%)
upper respiratory tract infection 3% (placebo 2.8%)
NCT00603278 · Phase 2
100 µg OD
headache 8.6% (placebo 5.6%)
nasopharyngitis 8.6% (placebo 7.5%)
diarrhoea 3.8% (placebo 0%)
NCT00603278 · Phase 2
400 µg OD
headache 9.1% (placebo 5.6%)
cough 4% (placebo 0.9%)
nasopharyngitis 4% (placebo 7.5%)
NCT00603278 · Phase 2
300 µg OD
headache 7.8% (placebo 5.6%)
nasopharyngitis 6.8% (placebo 7.5%)
back pain 2.9% (placebo 0%)
NCT00603278 · Phase 2
200 µg OD
dysphonia 4% (placebo 1%)
oropharyngeal candidiasis 4% (placebo 1%)
headache 3% (placebo 9.7%)
NCT00603746 · Phase 2
800 µg OD
headache 9.8% (placebo 9.7%)
nasopharyngitis 6.9% (placebo 3.9%)
oral candidiasis 6.9% (placebo 0%)
NCT00603746 · Phase 2
600 µg OD
headache 11.2% (placebo 9.7%)
back pain 3.7% (placebo 1%)
pharyngolaryngeal pain 2.8% (placebo 1%)
NCT00603746 · Phase 2
400 µg OD
headache 9.9% (placebo 9.7%)
dysphonia 5% (placebo 1%)
nasopharyngitis 5% (placebo 3.9%)
NCT00603746 · Phase 2
100 µg OD
nasopharyngitis 7.9% (placebo 5.2%)
bronchitis 7% (placebo 6.1%)
headache 6.1% (placebo 4.3%)
NCT01159912 · Phase 3
100/25 µg OD
nasopharyngitis 10% (placebo 7.4%)
headache 5% (placebo 3.9%)
NCT01165138 · Phase 3
200 µg OD
headache 12.6%
nasopharyngitis 12.6%
bronchitis 6.7%
NCT01431950 · Phase 3
100 µg OD
bronchitis 11.8%
nasopharyngitis 11.8%
headache 10.1%
NCT01431950 · Phase 3
200/25 µg OD
nasopharyngitis 12.7%
headache 5.6%
bronchitis 3.6%
NCT01134042 · Phase 3 · combination · Asthma · phase 3
100 µg OD
cough 8.5% (placebo 5%)
headache 5.9% (placebo 1.7%)
rhinorrhoea 5.1% (placebo 1.7%)
NCT01563029 · Phase 2
50 µg OD
pharyngitis 5.8% (placebo 3.4%)
bronchitis 3.3% (placebo 0.8%)
nasopharyngitis 3.3% (placebo 3.4%)
NCT01563029 · Phase 2
25 µg OD
nasopharyngitis 7.6% (placebo 3.4%)
cough 5.9% (placebo 5%)
oropharyngeal pain 5.1% (placebo 0.8%)
NCT01563029 · Phase 2
50 mcg
upper respiratory tract infection 12.2% (placebo 13.8%)
nasopharyngitis 9.7% (placebo 10.5%)
rhinitis 6.7% (placebo 7.5%)
NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy
nasopharyngitis 6.9% (placebo 8.3%)
headache 5.2% (placebo 13.3%)
cough 3.4% (placebo 5%)
NCT02502734 · Phase 3 · registry result, not featured evidence
100 mcg once daily
nasopharyngitis 17.9%
NCT02094937 · Phase 3 · registry result, not featured evidence
100/25 mcg once daily
nasopharyngitis 15.6%
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
200/25 µg OD
headache 8.4%
nasopharyngitis 7.2%
upper respiratory tract infection 2%
NCT01686633 · Phase 3 · registry result, not featured evidence
100/25 µg OD
headache 8.4%
nasopharyngitis 6.4%
upper respiratory tract infection 2.3%
NCT01686633 · Phase 3 · registry result, not featured evidence
50 µg OD
headache 14.5% (placebo 11.3%)
nasopharyngitis 6.8% (placebo 5.2%)
pharyngitis 6% (placebo 8.7%)
NCT01436110 · Phase 3 · registry result, not featured evidence
50 µg OD
nasopharyngitis 5.8% (placebo 4.1%)
headache 5% (placebo 11.6%)
pharyngitis 5% (placebo 5%)
NCT01436071 · Phase 3 · registry result, not featured evidence
100/25 µg
headache 18.6%
nasopharyngitis 15.4%
upper respiratory tract infection 7.2%
NCT01086384 · Phase 3 · registry result, not featured evidence
200/25 µg OD
headache 17.3%
upper respiratory tract infection 14.9%
nasopharyngitis 9.4%
NCT01018186 · Phase 3 · registry result, not featured evidence
100/25 µg OD
headache 19.4%
upper respiratory tract infection 16.9%
nasopharyngitis 12.4%
NCT01018186 · Phase 3 · registry result, not featured evidence
200/25 µg PM
headache 16.1% (placebo 8.6%)
back pain 3.6% (placebo 0%)
sinus headache 3.6% (placebo 0%)
NCT01086410 · Phase 3 · registry result, not featured evidence
100/25 µg PM
headache 26.8% (placebo 8.6%)
arthralgia 3.6% (placebo 0%)
nasopharyngitis 3.6% (placebo 1.7%)
NCT01086410 · Phase 3 · registry result, not featured evidence
100 µg AM
headache 52.2% (placebo 36%)
upper respiratory tract infection 26.1% (placebo 8%)
nasopharyngitis 8.7% (placebo 4%)
NCT01808339 · Phase 2 · registry result, not featured evidence
100 µg PM
headache 41.7% (placebo 36%)
viral upper respiratory tract infection 20.8% (placebo 8%)
dysmenorrhoea 8.3% (placebo 8%)
NCT01808339 · Phase 2 · registry result, not featured evidence
100 µg/25 µg
bronchitis 4%
conjunctivitis 4%
headache 4%
NCT01453023 · Phase 2 · registry result, not featured evidence
100/25 µg OD
headache 55.6% (placebo 40.7%)
nasopharyngitis 11.1% (placebo 7.4%)
oropharyngeal pain 11.1% (placebo 7.4%)
NCT01128595 · Phase 2 · registry result, not featured evidence
100 µg
headache 11.5% (placebo 0%)
acute tonsillitis 3.8% (placebo 0%)
cough 3.8% (placebo 0%)
NCT01332292 · Phase 2 · registry result, not featured evidence
100/25 µg OD
headache 9.8% (placebo 17.6%)
dysphonia 3.9% (placebo 0%)
mouth ulceration 3.9% (placebo 0%)
NCT01128569 · Phase 2 · registry result, not featured evidence
200 µg OD
upper respiratory tract infection 5% (placebo 1.1%)
NCT00766090 · Phase 2 · registry result, not featured evidence
100 µg BID
upper respiratory tract infection 4.9% (placebo 1.1%)
NCT00766090 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 4 of these studies.
  2. bPopulation comparability has not been reviewed for 41 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

albuterol / budesonide

Severe Exacerbation 22.9% (n=1054) vs 26.2% (n=1014) AS MDI80/180 μg
event rate · % of participants
NCT03769090 · Phase 3 · Asthma · phase 3 · converted to % from 241 Participants as posted
Severe Exacerbation Rate Annualized 0.49 vs 0.59 AS MDI per year80/180 μg
event rate · per year
NCT03769090 · Phase 3 · Asthma · phase 3
show 2 more results
0.15 vs 0.32 PT007 per year160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
0.15 vs 0.33 PT007 per year160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
ACQ-5 64.7% (n=1052) vs 62.1% (n=1014) AS MDI @ 24wk80/180 μg
responder rate · % of participants
NCT03769090 · Phase 3 · Asthma · phase 3 · converted to % from 681 Participants as posted
Time to First Severe Exacerbation 5.1% (n=1209) vs 9.1% (n=1212) PT007160/180 μg
event count · % of participants
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 62 Participants as posted
show 3 more results
5.3% (n=1209) vs 9.4% (n=1212) PT007*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 64 Participants as posted
6% (n=1180) vs 10.7% (n=1173) PT007*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 71 Participants as posted
6.2% (n=1180) vs 11.2% (n=1173) PT007*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 73 Participants as posted
Total Systemic Glucocorticoid Exposure mg Per 23.2 vs 61.9 PT007 per year160/180 μg
absolute value · per year
NCT05505734 · Phase 3 · Asthma · phase 3
show 1 more result
23 vs 63 PT007 per year160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
Total Systemic Glucocorticoid Duration 0.01 vs 0.03 PT007 months160/180 μg
absolute value · months
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to months from 0.4 days as posted
show 1 more result
0.01 vs 0.03 PT007 months*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to months from 0.4 days as posted
FEV1 AUC0-6 0.259 vs 0.097 placebo L @ 12wk160/180 μg
absolute change · L
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to L from 258.6 mL as posted
show 1 more result
0.242 vs 0.097 placebo L @ 12wk*80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to L from 242.2 mL as posted
Time to FEV1 15 Increase 7.5 vs 14 placebo minutes @ 0wk160/180 μg
absolute value · minutes
NCT03847896 · Phase 3 · Asthma · phase 3
show 1 more result
7 vs 14 placebo minutes @ 0wk80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
Duration of FEV1 15 Increase 185.5 vs 229.5 placebo minutes @ 0wk160/180 μg
absolute value · minutes
NCT03847896 · Phase 3 · Asthma · phase 3
show 1 more result
174 vs 229.5 placebo minutes @ 0wk80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
ACQ-7 66.5% (n=161) vs 55.3% (n=159) placebo @ 12wk160/180 μg
responder rate · % of participants
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to % from 107 Participants as posted
show 1 more result
65.5% (n=165) vs 55.3% (n=159) placebo @ 12wk*80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to % from 108 Participants as posted
FEV1 Max Fall 6.95% (n=64) vs 24.46% (n=64) placebo160/180
absolute value · percentage points
All subjects
NCT06245551 · Phase 3
FEV1 Max Fall LT 10 75% (n=64) vs 3.1% (n=64) placebo160/180
event count · % of participants
Maximum percentage fall <10%
NCT06245551 · Phase 3 · converted to % from 48 Participants as posted

+ 12 further endpoints in the CSV export.

Fluticasone Furoate

FEV1 Evening Trough 0.367 vs 0.137 placebo L @ 8wk200 µg OD
absolute change · L
NCT00603382 · Phase 2
show 3 more results
0.341 vs 0.137 placebo L @ 8wk100 µg OD
NCT00603382 · Phase 2
0.266 vs 0.137 placebo L @ 8wk50 µg OD
NCT00603382 · Phase 2
0.239 vs 0.137 placebo L @ 8wk25 µg OD
NCT00603382 · Phase 2
Evening PEF 31.3 vs 9.6 placebo L/min200 µg OD
absolute change · L/min
NCT00603382 · Phase 2
show 20 more results
14.8 vs -2.8 placebo L/min200 µg OD
NCT00603278 · Phase 2
11.9 vs -5.1 placebo L/min200 µg OD
NCT00603746 · Phase 2
41.7 vs 15.5 FF L/min @ 12wk200/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
25.7 vs 9.6 placebo L/min100 µg OD
NCT00603382 · Phase 2
9.1 vs -2.8 placebo L/min100 µg OD
NCT00603278 · Phase 2
26.4 vs -1.8 placebo L/min @ 12wk100/25 µg OD
NCT01165138 · Phase 3
13.5 vs 5.1 placebo L/min @ 12wk100 µg OD
NCT01563029 · Phase 2
11 vs 5 placebo L/min @ 12wk100 µg OD
NCT01563029 · Phase 2
39.7 vs 15.5 FF L/min @ 12wk100/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
30.3 vs 9.6 placebo L/min50 µg OD
NCT00603382 · Phase 2
18.5 vs 5.1 placebo L/min @ 12wk50 µg OD
NCT01563029 · Phase 2
18.2 vs 5 placebo L/min @ 12wk50 µg OD
NCT01563029 · Phase 2
16.3 vs -5.1 placebo L/min800 µg OD
NCT00603746 · Phase 2
11.7 vs -5.1 placebo L/min600 µg OD
NCT00603746 · Phase 2
21 vs -2.8 placebo L/min400 µg OD
NCT00603278 · Phase 2
14.5 vs -5.1 placebo L/min400 µg OD
NCT00603746 · Phase 2
15.1 vs -2.8 placebo L/min300 µg OD
NCT00603278 · Phase 2
23.6 vs 9.6 placebo L/min25 µg OD
NCT00603382 · Phase 2
16.3 vs 5.1 placebo L/min @ 12wk25 µg OD
NCT01563029 · Phase 2
16.2 vs 5 placebo L/min @ 12wk25 µg OD
NCT01563029 · Phase 2
Morning PEF 35.6 vs 13.6 placebo L/min200 µg OD
absolute change · L/min
NCT00603382 · Phase 2
show 22 more results
16 vs -4.7 placebo L/min200 µg OD
NCT00603278 · Phase 2
19.6 vs -7.3 placebo L/min200 µg OD
NCT00603746 · Phase 2
47.7 vs 19.1 FF L/min @ 12wk200/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
29.5 vs 13.6 placebo L/min100 µg OD
NCT00603382 · Phase 2
15.6 vs -4.7 placebo L/min100 µg OD
NCT00603278 · Phase 2
32.9 vs -0.4 placebo L/min @ 12wk100/25 µg OD
NCT01165138 · Phase 3
15.8 vs 3.3 placebo L/min @ 12wk100 µg OD
NCT01563029 · Phase 2
14.2 vs 2.7 placebo L/min @ 12wk100 µg OD
NCT01563029 · Phase 2
44.3 vs 19.1 FF L/min @ 12wk100/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
33.5 vs 13.6 placebo L/min50 µg OD
NCT00603382 · Phase 2
22.8 vs 3.3 placebo L/min @ 12wk50 µg OD
NCT01563029 · Phase 2
20.6 vs 2.7 placebo L/min @ 12wk50 µg OD
NCT01563029 · Phase 2
30 vs 10.8 placebo L/min50 µg OD
NCT01436110 · Phase 3 · registry result, not featured evidence
34.5 vs 22.9 placebo L/min @ 12wk50 µg OD
NCT01436071 · Phase 3 · registry result, not featured evidence
20.7 vs -7.3 placebo L/min800 µg OD
NCT00603746 · Phase 2
16.7 vs -7.3 placebo L/min600 µg OD
NCT00603746 · Phase 2
26 vs -4.7 placebo L/min400 µg OD
NCT00603278 · Phase 2
20.9 vs -7.3 placebo L/min400 µg OD
NCT00603746 · Phase 2
25.5 vs -4.7 placebo L/min300 µg OD
NCT00603278 · Phase 2
27.2 vs 13.6 placebo L/min25 µg OD
NCT00603382 · Phase 2
21.9 vs 3.3 placebo L/min @ 12wk25 µg OD
NCT01563029 · Phase 2
23.3 vs 2.7 placebo L/min @ 12wk25 µg OD
NCT01563029 · Phase 2
Symptom-free 24-h Period 31.7% (n=95) vs 18.4% (n=94) placebo200 µg OD
percent change · % of baseline
NCT00603382 · Phase 2
show 16 more results
19.4% (n=101) vs 17.1% (n=107) placebo200 µg OD
NCT00603278 · Phase 2
20.1% (n=99) vs 6.4% (n=101) placebo200 µg OD
NCT00603746 · Phase 2
29% (n=346) vs 19.4% (n=346) FF @ 12wk200/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
38.7% (n=110) vs 18.4% (n=94) placebo100 µg OD
NCT00603382 · Phase 2
21.3% (n=104) vs 17.1% (n=107) placebo100 µg OD
NCT00603278 · Phase 2
19.3% (n=112) vs 10.4% (n=114) placebo @ 24wk100 µg OD
NCT01159912 · Phase 3
32.5% (n=201) vs 14.6% (n=202) placebo @ 12wk100/25 µg OD
NCT01165138 · Phase 3
27.2% (n=345) vs 19.4% (n=346) FF @ 12wk100/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
31.1% (n=98) vs 18.4% (n=94) placebo50 µg OD
NCT00603382 · Phase 2
22.6% (n=111) vs 14% (n=110) placebo @ 12wk50 µg OD
NCT01436071 · Phase 3 · registry result, not featured evidence
18.5% (n=101) vs 6.4% (n=101) placebo800 µg OD
NCT00603746 · Phase 2
15.1% (n=107) vs 6.4% (n=101) placebo600 µg OD
NCT00603746 · Phase 2
28% (n=99) vs 17.1% (n=107) placebo400 µg OD
NCT00603278 · Phase 2
19.6% (n=101) vs 6.4% (n=101) placebo400 µg OD
NCT00603746 · Phase 2
24.1% (n=102) vs 17.1% (n=107) placebo300 µg OD
NCT00603278 · Phase 2
25.3% (n=96) vs 18.4% (n=94) placebo25 µg OD
NCT00603382 · Phase 2
Rescue-free 24-h Period 32% (n=95) vs 21.9% (n=94) placebo200 µg OD
percent change · % of baseline
NCT00603382 · Phase 2
show 17 more results
23.8% (n=101) vs 15.6% (n=107) placebo200 µg OD
NCT00603278 · Phase 2
17.9% (n=99) vs 3.6% (n=101) placebo200 µg OD
NCT00603746 · Phase 2
35.8% (n=346) vs 22.6% (n=346) FF @ 12wk200/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
40.8% (n=110) vs 21.9% (n=94) placebo100 µg OD
NCT00603382 · Phase 2
25% (n=104) vs 15.6% (n=107) placebo100 µg OD
NCT00603278 · Phase 2
21.3% (n=112) vs 6.5% (n=114) placebo @ 24wk100 µg OD
NCT01159912 · Phase 3
37.1% (n=201) vs 17.8% (n=202) placebo @ 12wk100/25 µg OD
NCT01165138 · Phase 3
34.8% (n=345) vs 22.6% (n=346) FF @ 12wk100/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
34.5% (n=98) vs 21.9% (n=94) placebo50 µg OD
NCT00603382 · Phase 2
28.9% (n=116) vs 21.1% (n=114) placebo50 µg OD
NCT01436110 · Phase 3 · registry result, not featured evidence
28.7% (n=111) vs 17.1% (n=110) placebo @ 12wk50 µg OD
NCT01436071 · Phase 3 · registry result, not featured evidence
22.3% (n=101) vs 3.6% (n=101) placebo800 µg OD
NCT00603746 · Phase 2
17.4% (n=107) vs 3.6% (n=101) placebo600 µg OD
NCT00603746 · Phase 2
24.4% (n=99) vs 15.6% (n=107) placebo400 µg OD
NCT00603278 · Phase 2
21.1% (n=101) vs 3.6% (n=101) placebo400 µg OD
NCT00603746 · Phase 2
25% (n=102) vs 15.6% (n=107) placebo300 µg OD
NCT00603278 · Phase 2
29.3% (n=96) vs 21.9% (n=94) placebo25 µg OD
NCT00603382 · Phase 2
Evening PEF 2.2 vs 0.4 placebo L @ 12wk100 µg OD
absolute change · L
PM PEF, Week 1 to 12
NCT01159912 · Phase 3
Evening PEF 1.5 vs -1.3 placebo L @ 24wk100 µg OD
absolute change · L
PM PEF, Week 1 to 24
NCT01159912 · Phase 3
Morning PEF 13.2 vs 5.7 placebo L @ 12wk100 µg OD
absolute change · L
AM PEF, Week 1 to 12
NCT01159912 · Phase 3
Morning PEF 13.9 vs 5 placebo L @ 24wk100 µg OD
absolute change · L
AM PEF, Week 1 to 24
NCT01159912 · Phase 3
AQLQ Total 0.69 vs 0.45 placebo score @ 12wk100 µg OD
absolute change · score
NCT01159912 · Phase 3
show 4 more results
0.84 vs 0.51 placebo score @ 24wk100 µg OD
NCT01159912 · Phase 3
0.91 vs 0.61 placebo score @ 12wk100/25 µg OD
NCT01165138 · Phase 3
0.74 vs 0.66 FF score @ 12wk200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
0.93 vs 0.88 FF score @ 24wk200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
FEV1 Wm0 24 h 0.499 vs 0.366 FF L @ 12wk200/25 µg OD
absolute change · L
NCT01686633 · Phase 3 · registry result, not featured evidence
show 5 more results
0.513 vs 0.212 placebo L @ 12wk100/25 µg OD
NCT01165138 · Phase 3
0.474 vs 0.366 FF L @ 12wk100/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
3.303 vs 3.227 placebo L @ 2wk100 µg AM
NCT01808339 · Phase 2 · registry result, not featured evidence
3.332 vs 3.227 placebo L @ 2wk100 µg PM
NCT01808339 · Phase 2 · registry result, not featured evidence
0.464 vs 0.328 FF L @ 24wk200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
FEV1 Trough 2.714 vs 2.605 placebo L @ 4wk200 µg OD
absolute value · L
NCT00766090 · Phase 2 · registry result, not featured evidence
show 2 more results
2.83 vs 2.462 placebo L @ 12wk100/25 µg OD
NCT01165138 · Phase 3
2.703 vs 2.605 placebo L @ 4wk100 µg BID
NCT00766090 · Phase 2 · registry result, not featured evidence

+ 30 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol / budesonide's landscape · Fluticasone Furoate's landscape